A Study of DS-3939a in Participants With Solid Tumors

The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.

Trial Details

NCT ID

NCT07739966

Phase

PHASE1 / PHASE2

Sponsor

Daiichi Sankyo

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

DS-3939a
Pembrolizumab
Carboplatin
Pemetrexed
DS-1103a

Locations (sample)

Fayetteville, Arkansas, United States|36.06258,-94.15743
Los Angeles, California, United States|34.05223,-118.24368
Tampa, Florida, United States|27.94752,-82.45843
Portland, Oregon, United States|45.52345,-122.67621
Providence, Rhode Island, United States|41.82399,-71.41283

Key Eligibility Criteria

Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures.
Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age …
Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC.
Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →